Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors
← catalyst calendarNCT05887492 · readout ≤ 42 d
Sponsored by Tango Therapeutics, Inc. (industry) · TNGX — their whole pipeline →.
Phase
Phase 1/2
Status
Active, not recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
126estimated
Sites
13
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-06-12 | actual | When the study began enrolling |
| Primary completion | Sep 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Sep 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2023-06-02 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-06 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Non Small Cell Lung Cancer
- Solid Tumors, Adult
- Lung Cancer
- Lung Adenocarcinoma
Interventions
- Drug: TNG260
- Drug: Pembrolizumab — also filed as Keytruda
Primary outcomes
what the primary-completion date above is the date OFDetermine the MTD and RP2D(s) (Phase 1 only)
measured 42 days
Measure antitumor activity using RECIST 1.1 (Phase 2 only)
measured 12 weeks
Permalink · TNGX's whole pipeline · Catalyst calendar · Every registered study · What changed